Remote Phase I Oncology CRA: First-in-Human Trials

Piper Companies; United States; A distancia; USD 110.000 - 140.000; Jornada completa

Ventajas ofrecidas por este puesto de trabajo

Health insurance

Vision insurance

Dental insurance

Paid time off

Paid holidays

Sick leave as required by law

Descripción de la vacante

Piper Companies is seeking a Phase I Oncology Clinical Research Associate to support early-phase oncology trials. This remote role requires travel up to 8-10 days per month and focuses on first-in-human dose-escalation studies.

The ideal candidate has 3+ years of onsite CRA experience in Phase I/early oncology, a Bachelor’s degree, and hands-on experience with dose-escalation and DLTs. Comprehensive benefits are included.

Formación

• 3+ years of onsite monitoring as a CRA with a focus on Phase I or early-phase oncology.
• Bachelor’s Degree is required.
• Hands-on experience with dose-escalation and DLTs.
• Strong knowledge of GCP, FDA regulations, and monitoring best practices.
• Experience with oncology indications and EDC systems.
• Ability to travel to research sites as required.

Responsabilidades

• Monitor Phase I and first-in-human oncology trials in compliance with ICH-GCP and FDA regulations.
• Conduct site initiation, monitoring, and close-out visits.
• Ensure subject safety, data quality, and protocol adherence.
• Review source documents, EDC data, and safety reports.
• Collaborate with sites and internal clinical teams to resolve issues.

Conocimientos

Onsite monitoring

Phase I oncology

GCP & FDA knowledge

Data review (EDC)

Travel readiness

Educación

Bachelor’s Degree

Herramientas

EDC systems

Descripción del empleo

Piper Companies is seeking a Phase I Oncology Clinical Research Associate to support early-phase oncology trials. This remote role requires travel up to 8-10 days per month and focuses on first-in-human dose-escalation studies.

The ideal candidate has 3+ years of onsite CRA experience in Phase I/early oncology, a Bachelor’s degree, and hands-on experience with dose-escalation and DLTs. Comprehensive benefits are included.